205 related articles for article (PubMed ID: 23325837)
1. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
Walter RB; Othus M; Burnett AK; Löwenberg B; Kantarjian HM; Ossenkoppele GJ; Hills RK; van Montfort KG; Ravandi F; Evans A; Pierce SR; Appelbaum FR; Estey EH
Blood; 2013 Mar; 121(13):2424-31. PubMed ID: 23325837
[TBL] [Abstract][Full Text] [Related]
2. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.
Canaani J; Beohou E; Labopin M; Socié G; Huynh A; Volin L; Cornelissen J; Milpied N; Gedde-Dahl T; Deconinck E; Fegueux N; Blaise D; Mohty M; Nagler A
Am J Hematol; 2017 Apr; 92(4):344-350. PubMed ID: 28052366
[TBL] [Abstract][Full Text] [Related]
3. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
4. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
5. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
Walter RB; Othus M; Burnett AK; Löwenberg B; Kantarjian HM; Ossenkoppele GJ; Hills RK; Ravandi F; Pabst T; Evans A; Pierce SR; Vekemans MC; Appelbaum FR; Estey EH
Leukemia; 2015 Feb; 29(2):312-20. PubMed ID: 25113226
[TBL] [Abstract][Full Text] [Related]
6. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
7. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group.
Kinoshita A; Miyachi H; Matsushita H; Yabe M; Taki T; Watanabe T; Saito AM; Tomizawa D; Taga T; Takahashi H; Matsuo H; Kodama K; Ohki K; Hayashi Y; Tawa A; Horibe K; Adachi S
Br J Haematol; 2014 Oct; 167(1):80-6. PubMed ID: 25039450
[TBL] [Abstract][Full Text] [Related]
11. Subtype-specific patterns of molecular mutations in acute myeloid leukemia.
Rose D; Haferlach T; Schnittger S; Perglerová K; Kern W; Haferlach C
Leukemia; 2017 Jan; 31(1):11-17. PubMed ID: 27285584
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Klaus M; Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
Cancer Genet Cytogenet; 2004 Nov; 155(1):47-56. PubMed ID: 15527902
[TBL] [Abstract][Full Text] [Related]
13. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
14. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
[TBL] [Abstract][Full Text] [Related]
15. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes.
Venditti A; Del Poeta G; Buccisano F; Tamburini A; Cox MC; Stasi R; Bruno A; Aronica G; Maffei L; Suppo G; Simone MD; Forte L; Cordero V; Postorino M; Tufilli V; Isacchi G; Masi M; Papa G; Amadori S
Blood; 1997 Jan; 89(2):621-9. PubMed ID: 9002966
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
17. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
18. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG;
Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
[TBL] [Abstract][Full Text] [Related]
19. Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations.
Selheim F; Aasebø E; Reikvam H; Bruserud Ø; Hernandez-Valladares M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791118
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5.
Cheng Z; Hu K; Tian L; Dai Y; Pang Y; Cui W; Zhao H; Qin T; Han Y; Hu N; Chen L; Wang C; Zhang Y; Wu D; Ke X; Shi J; Fu L
Cancer Gene Ther; 2018 May; 25(3-4):77-83. PubMed ID: 29491461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
